1. 3MO Comprehensive biomarkers (BMS) analysis to predict efficacy of PD1/L1 immune checkpoint inhibitors (ICIs) in combination with chemotherapy: A subgroup analysis of the precision immuno-oncology for advanced non-small cell lung cancer (pioneer) trial. (December 2022) Authors: Barlesi, F.; Greillier, L.; Monville, F.; Audigier Valette, C.; Martinez, S.; Cloarec, N.; Van Hulst, S.; Odier, L.; Vely, F.; Juquel, L.; Arnaud, L.; Bokobza, S.; Hamimed, M.; Karlsen, M.; Dufosse, P.; Pouchin, A.; Ghezali, L.; Le Ray, M.; Fieschi-Meric, J.; Benzekry, S. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗